Enliven Therapeutics, Inc. (ELVN) — Net Income
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | -$103.69M | -16.5% |
| 2024 | -$89.02M | -24.4% |
| 2023 | -$71.58M | -90.1% |
| 2022 | -$37.66M | +26.7% |
| 2021 | -$51.38M | -24.2% |
| 2020 | -$41.36M | -76.3% |
| 2019 | -$23.46M | — |
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | -$103.69M | -16.5% |
| 2024 | -$89.02M | -24.4% |
| 2023 | -$71.58M | -90.1% |
| 2022 | -$37.66M | +26.7% |
| 2021 | -$51.38M | -24.2% |
| 2020 | -$41.36M | -76.3% |
| 2019 | -$23.46M | — |